Search hospitals > Ohio > Toledo
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
Claim this profileToledo, Ohio 43606
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Tumors
Conducts research for Leukemia
Conducts research for Lymphoma
293 reported clinical trials
12 medical researchers
Summary
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital is a medical facility located in Toledo, Ohio. This center is recognized for care of Cancer, Recurrence, Tumors, Leukemia, Lymphoma and other specialties. ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital is involved with conducting 293 clinical trials across 514 conditions. There are 12 research doctors associated with this hospital, such as Jamie L. Dargart, Abhijit B. Saste, Adam C. Walter, and Jeffrey H. Muler.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Recurrence
Global LeaderStage IV
Stage III
Stage II
Top PIs
Jamie L. DargartProMedica Toledo Hospital/Russell J Ebeid Children's Hospital7 years of reported clinical research
Expert in Tumors
Expert in Cancer
53 reported clinical trials
108 drugs studied
Abhijit B. SasteProMedica Flower Hospital5 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
12 reported clinical trials
28 drugs studied
Adam C. WalterProMedica Flower Hospital6 years of reported clinical research
Studies Cancer
Studies Adenocarcinoma
9 reported clinical trials
24 drugs studied
Jeffrey H. MulerProMedica Flower Hospital1 year of reported clinical research
Studies Cancer
Studies Bladder Cancer
10 reported clinical trials
27 drugs studied
Clinical Trials running at ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Osteosarcoma
Germ Cell Tumors
Brain Tumor
Rhabdomyosarcoma
Non-Hodgkin's Lymphoma
Langerhans Cell Histiocytosis
Neuroblastoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Symptom Monitoring
for Young Women on Hormone Therapy
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital?
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital is a medical facility located in Toledo, Ohio. This center is recognized for care of Cancer, Recurrence, Tumors, Leukemia, Lymphoma and other specialties. ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital is involved with conducting 293 clinical trials across 514 conditions. There are 12 research doctors associated with this hospital, such as Jamie L. Dargart, Abhijit B. Saste, Adam C. Walter, and Jeffrey H. Muler.